KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Non-Current Assets (2017 - 2026)

Aquestive Therapeutics has reported Other Non-Current Assets over the past 9 years, most recently at $2.6 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 37.44% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, down 37.44%, while the annual FY2025 figure was $2.6 million, 37.44% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $2.6 million at Aquestive Therapeutics, down from $3.2 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $7.8 million in Q1 2021 and troughed at $2.6 million in Q4 2025.
  • A 5-year average of $5.4 million and a median of $5.5 million in 2023 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 2620.49% in 2021 and later plummeted 37.44% in 2025.
  • Year by year, Other Non-Current Assets stood at $6.9 million in 2021, then fell by 6.55% to $6.5 million in 2022, then decreased by 15.7% to $5.4 million in 2023, then fell by 22.34% to $4.2 million in 2024, then plummeted by 37.44% to $2.6 million in 2025.
  • Business Quant data shows Other Non-Current Assets for AQST at $2.6 million in Q4 2025, $3.2 million in Q3 2025, and $3.2 million in Q2 2025.